Letrozole in Treating Polycystic Ovary Syndrome-Associated Infertility

Rihab Kadhim; Amal Umran Mosa; Hameedah Hadi AbdulWahid

doi:10.62472/kjps.v16.i26.48-63

المؤلفون

Rihab Kadhim Pharmacology and Toxicology department, College of Pharmacy, University of Karbala, Iraq
Amal Umran Mosa Pharmacology and Toxicology department, College of Pharmacy, University of Karbala, Iraq
Hameedah Hadi AbdulWahid Consultant Gynecologist, Warith Al-Anbiya University, College of Medicine

DOI:

https://doi.org/10.62472/kjps.v16.i26.48-63

الكلمات المفتاحية:

Ovulation، prolactin، PCOS، egg size، LH، Letrozole، endometrial thickness

الملخص

Letrozole was originally reported for the treatment of breast malignancy, however, it exhibited potential in treating infertility disorders linked with polycystic ovary syndrome (PCOS). The purpose of this research was to investigate the usefulness of letrozole in treating infertile females with PCOS. A randomized, prospective, clinical trial involving 105 females aged between 19 and 33 was performed. Over a couple of months, evaluations were completed on days two and twelve of the females who received letrozole tablets. Substantial statistical ovulatory increment, more endometrial thickness, and altered hormone levels were identified. These changes signify letrozole's potential as a useful choice for PCOS-associated infertility. To fully comprehend its therapeutic potential and optimize treatment regimens, additional future study is required.